Current and emerging options in the treatment of onychomycosis

Boni Elewski, David Pariser, Phoebe Rich, Richard K. Scher

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Currently approved options for the treatment of onychomycosis include systemic therapy (the antifungal agents fluconazole, itraconazole, and terbinafine), topical agents (ciclopirox, which has been available since 1996, efinaconazole, currently pending approval), and laser systems. Phase III studies on another topical, tavaborole, have been completed and this medication also shows promise. Mechanical modalities are sometimes used but are seldom necessary. Recurrence of infection is common; the risk for recurrence may be reduced by adherence to preventive measures, especially avoiding (if possible) or promptly treating tinea pedis infections.

Original languageEnglish (US)
Pages (from-to)S9-S12
JournalSeminars in cutaneous medicine and surgery
Volume32
DOIs
StatePublished - Jun 1 2013

Fingerprint

Onychomycosis
ciclopirox
terbinafine
Tinea Pedis
Recurrence
Itraconazole
Fluconazole
Antifungal Agents
Infection
Lasers
Therapeutics
efinaconazole
tavaborole

Keywords

  • Ciclopirox
  • Efinaconazole
  • Fluconazole
  • Fungal infections
  • Itraconazole
  • Nail infections
  • Onychomycosis
  • Tavaborole
  • Terbinafines

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Dermatology

Cite this

Current and emerging options in the treatment of onychomycosis. / Elewski, Boni; Pariser, David; Rich, Phoebe; Scher, Richard K.

In: Seminars in cutaneous medicine and surgery, Vol. 32, 01.06.2013, p. S9-S12.

Research output: Contribution to journalArticle

Elewski, Boni ; Pariser, David ; Rich, Phoebe ; Scher, Richard K. / Current and emerging options in the treatment of onychomycosis. In: Seminars in cutaneous medicine and surgery. 2013 ; Vol. 32. pp. S9-S12.
@article{36bbb6b83c634848b5864f317e6c07b4,
title = "Current and emerging options in the treatment of onychomycosis",
abstract = "Currently approved options for the treatment of onychomycosis include systemic therapy (the antifungal agents fluconazole, itraconazole, and terbinafine), topical agents (ciclopirox, which has been available since 1996, efinaconazole, currently pending approval), and laser systems. Phase III studies on another topical, tavaborole, have been completed and this medication also shows promise. Mechanical modalities are sometimes used but are seldom necessary. Recurrence of infection is common; the risk for recurrence may be reduced by adherence to preventive measures, especially avoiding (if possible) or promptly treating tinea pedis infections.",
keywords = "Ciclopirox, Efinaconazole, Fluconazole, Fungal infections, Itraconazole, Nail infections, Onychomycosis, Tavaborole, Terbinafines",
author = "Boni Elewski and David Pariser and Phoebe Rich and Scher, {Richard K.}",
year = "2013",
month = "6",
day = "1",
doi = "10.12788/j.sder.0016",
language = "English (US)",
volume = "32",
pages = "S9--S12",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Current and emerging options in the treatment of onychomycosis

AU - Elewski, Boni

AU - Pariser, David

AU - Rich, Phoebe

AU - Scher, Richard K.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Currently approved options for the treatment of onychomycosis include systemic therapy (the antifungal agents fluconazole, itraconazole, and terbinafine), topical agents (ciclopirox, which has been available since 1996, efinaconazole, currently pending approval), and laser systems. Phase III studies on another topical, tavaborole, have been completed and this medication also shows promise. Mechanical modalities are sometimes used but are seldom necessary. Recurrence of infection is common; the risk for recurrence may be reduced by adherence to preventive measures, especially avoiding (if possible) or promptly treating tinea pedis infections.

AB - Currently approved options for the treatment of onychomycosis include systemic therapy (the antifungal agents fluconazole, itraconazole, and terbinafine), topical agents (ciclopirox, which has been available since 1996, efinaconazole, currently pending approval), and laser systems. Phase III studies on another topical, tavaborole, have been completed and this medication also shows promise. Mechanical modalities are sometimes used but are seldom necessary. Recurrence of infection is common; the risk for recurrence may be reduced by adherence to preventive measures, especially avoiding (if possible) or promptly treating tinea pedis infections.

KW - Ciclopirox

KW - Efinaconazole

KW - Fluconazole

KW - Fungal infections

KW - Itraconazole

KW - Nail infections

KW - Onychomycosis

KW - Tavaborole

KW - Terbinafines

UR - http://www.scopus.com/inward/record.url?scp=84891609312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891609312&partnerID=8YFLogxK

U2 - 10.12788/j.sder.0016

DO - 10.12788/j.sder.0016

M3 - Article

C2 - 24156162

AN - SCOPUS:84891609312

VL - 32

SP - S9-S12

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

ER -